Publications

Advani RH, Kelsey CR, Armand P, Bello CM, Benitez CM, Bond D, Chen W, Cherian S, Czader M, Dabaja B, Daly ME, Frosch Z, Gordon LI, Hansen N, Herrera AF, Hochberg EP, Hoppe RT, Isufi I, Johnston PB, Kelly K, Kenkre VP, Kline J, Lynch RC, McConathy J, Morgan D, Niu A, Paul S, Rabinovitch R, Salavati A, Sano D, Shah H, Spinner M, Svoboda J, Winter JN, Yahalom J, Yang JC, Montgomery S, Stehman K. Hodgkin Lymphoma, Version 1.2026, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41671432

Ma S, Spinner MA. Optimizing the Role of Checkpoint Inhibitors in the Management of Hodgkin Lymphoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2026. PMID: 41698326

O'Reilly EM, Cabanski CR, Lyman JP, Wainberg ZA, Fisher GA, Wolff RA, Ko AH, O'Hara MH, Spencer CN, Yu JX, Da Silva DM, Padrón LJ, Arnott J, Fairchild J, Moore JS, Peng B, Hoos WA, O'Donnell-Tormey J, Boffo S, Dugan U, Kimmelman AC, Amaravadi RK, Vonderheide RH. Clinical and translational results from a phase 1 trial of gemcitabine/nab-paclitaxel with nivolumab/ipilimumab or hydroxychloroquine/ipilimumab in untreated metastatic pancreatic adenocarcinoma. Journal for immunotherapy of cancer. 2026. PMID: 41617393

Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, André F, Im SA, Goncalves MD, Lacouture ME, Fasching PA, Leung R. Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer. ESMO open. 2026. PMID: 41604817

Foisey MG, Garcia J, Li X, Yang X, Hilburger C, Thienpont C, Chaves-Martinez A, Belkaya S, Truong T, Zhu I, Liu R, Hyrenius-Wittsten A, Almeida R, Shy BR, Allen GM, Wyman S, Roybal KT. Synthetic Hybrid Receptors for Safer and Programmable T Cell Therapy. bioRxiv : the preprint server for biology. 2026. PMID: 41648153

Luck C, Luo Y, Vasileva E, Jacobs KA, Riad J, Macaraig CD, Ponce RKM, Amatruda JF, Okimoto RA. Modeling of Capicua Family Fusion Oncoprotein-Driven Cancers Reveals Gene-Specific Functionality. Molecular cancer research : MCR. 2026. PMID: 41575738

Martin TG, van de Donk NWCJ, Rodríguez-Otero P, Mateos MV, Kobos R, Chastain K, Doyle M, Nooka AK. Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma. Future oncology (London, England). 2026. PMID: 41574880

Bidkar AP, Bidlingmaier S, Wadhwa A, Mayne E, Raveendran A, Naik S, Xue C, Basak M, Bobba KN, Patiño-Escobar B, Greenland N, Camara Serrano JA, Steri V, Chou J, Wiita A, He J, Wilson DM, Aggarwal R, VanBrocklin HF, Seo Y, Liu B, Flavell RR. Synergistic treatment of prostate cancer and multiple myeloma using CD46-targeted radioimmunotherapy-antibody drug conjugates. Clinical cancer research : an official journal of the American Association for Cancer Research. 2026. PMID: 41569419

Herasymenko O, Silva M, Correy GJ, Abu-Saleh AAA, Ackloo S, Arrowsmith C, Ashworth A, Ban F, Beck H, Bishop KP, Bohórquez HJ, Bolotokova A, Breznik M, Chau I, Chen Y, Cherkasov A, Dehaen W, Della Corte D, Denzinger K, Doering NP, Edfeldt K, Edwards A, Fayne D, Gentile F, Gibson E, Gokdemir O, Gunnarsson A, Günther J, Irwin JJ, Jensen JH, Harding RJ, Hillisch A, Hoffer L, Hogner A, Hutchinson A, Kandwal S, Karlova A, Koirala K, Kotelnikov S, Kozakov D, Lee J, Lee S, Lessel U, Liu S, Liu X, Loppnau P, Meiler J, Moretti R, Moroz YS, Muvva C, Oprea TI, Paige B, Pandit A, Park K, Poda G, Protopopov MV, Pütter V, Ravichandran R, Rognan D, Rosta E, Sabnis Y, Scott T, Seitova A, Sharma P, Sindt F, Song M, Steinmann C, Stevens R, Talagayev V, Tararina VV, Tarkhanova O, Tingey D, Trant JF, Treleaven D, Tropsha A, Walters P, Wells J, Westermaier Y, Wolber G, Wortmann L, Zheng S, Fraser JS, Schapira M. CACHE Challenge #3: Targeting the Nsp3 Macrodomain of SARS-CoV-2. Journal of chemical information and modeling. 2026. PMID: 41565251

Pan S, Fernández-Maestre I, Chang KC, Van Haver S, Wereski MG, Haugh AM, Tsai KK, Daud AI, Bowman RL, Vasudevan HN, Levine RL, Abate AR. PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells. Nature communications. 2026. PMID: 41565684

Li T, Ilano A, Arias-Badia M, Luong D, Chang H, Kwek SS, Allaire K, Chumber A, Sakamoto M, Clark M, Lea A, Bridge M, Chen B, Liu E, Porten S, Meng MV, Erlich LIR, Oh DY, Fong L. Functionally heterogeneous intratumoral CD4+CD8+ double-positive T cells can give rise to single-positive T cells. Proceedings of the National Academy of Sciences of the United States of America. 2026. PMID: 41557789

Tolaney SM, Sammons S, Sandoval-Leon A, Cortes J, Liepa AM, Grimes BR, He D, Cui ZL, Roose J, Gathirua-Mwangi W, Moreira K, O'Shaughnessy J, Neven P, Johnston SRD, Rugo HS. Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data. ESMO open. 2026. PMID: 41558202

Hertz DL, Venook AP. Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2026. PMID: 41632507

Tsui M, Hu K, Song H, Hsu SC, Chen YA, Nuniz L, Pham JH, Chang CH, Hui KSF, Quigley DA, Li J, Huang FW. Landscape of allele-specific expression in prostate cancer reveals recurrent, stage-specific events in AR signaling and resistance pathways. Molecular cancer research : MCR. 2026. PMID: 41543497

Popescu B, Jones MF, Piao M, Tran E, Koh A, Lomeli I, Peretz CAC, Murad N, Abelson S, Morales C, Rivera JM, Batingana AR, D'Souza J, Pikman Y, Cheng ML, Logan AC, Huang BJ, Stieglitz E, Smith CC. Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML. Blood. 2026. PMID: 41144772

Valtis YK, Lin C, Nemirovsky D, Devlin S, Rejeski K, Curran KJ, Wang X, Shah NN, Jeyakumar N, Miller K, Zhang A, Kota VK, Al Darobi AH, Muhsen I, Sasine J, Aldoss I, Advani AS, Reshef R, Chen EC, Kopmar N, Tsai SB, Hilal T, Shah BD, Faramand R, Solh MM, Tan V, Bezerra E, Battiwalla M, Ramakrishnan A, Mathews J, Shaughnessy P, Mountjoy L, Hoeg RT, Dykes KC, Logan AC, Kumaran MV, Schwartz M, Tracy S, Moore J, Odstrcil Bobillo S, Frey NV, Connor M, Ladha A, Dholaria B, Sutherland K, Roloff GW, Muffly LS, Park JH. CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia. Blood advances. 2026. PMID: 41052404

Jang A, Jindal T, Khaki AR, Jiang CY, Alhalabi O, Nguyen CB, Tsung I, Oh E, Epstein I, Bakaloudi DR, Jaime-Casas S, Nizam A, Glover M, Mabey H, Taylor A, Evans S, Shin D, Pywell C, Abuqayas B, Barata PC, Zakharia Y, Basu A, Kilari D, Bilen MA, Emamekhoo H, Milowsky M, Hoimes CJ, Davis N, Shah S, Gupta S, Tripathi A, Grivas P, Bellmunt J, Alva A, Campbell MT, Chen Z, Fu P, Koshkin VS, Brown JR. Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database. Clinical genitourinary cancer. 2026. PMID: 41644316

So J, Droznin AD, Tiwari P, Chen YH, Chau NG, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald KJ, Sehgal K, Li S, Gunasti L, Kim E, Minken J, Baginska J, Nau A, Diaz IG, Shim B, Janes JT, Uppaluri R, Haddad RI, Livak KJ, Schoenfeld JD. Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. International journal of radiation oncology, biology, physics. 2026. PMID: 41520892

Jabbour E, Sandhu KS, Shaughnessy P, Logan AC, Abedi M, Shah BD, Bishop MR, Park JH, DeAngelo DJ, Tholouli E, Yallop D, Chaganti S, Hodby K, Barba P, Guerreiro M, Menne T, Shang J, Lao-Sirieix P, Brugger W, Roddie C. Tumor burden-guided dosing contributes to mitigation of immunotoxicities following treatment with obecabtagene autoleucel in adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Haematologica. 2026. PMID: 41504229

Kenfield SA, Hart NH, Courneya KS, Greenwood R, Chan JM, Sison J, Zhang L, Rudman S, Ung L, Schumann M, Van Blarigan EL, McKeown S, Ryan CJ, Catto J, Galvão DA, Newton RU, Saad F, INTERVAL-GAP4 Site Investigators and INTERVAL-GAP4 Steering and Management Committees. Feasibility and Implementation of INTERVAL-GAP4: A Global Randomised Controlled Trial of Intense Hybrid-supervised/Self-managed Versus Self-directed Exercise for Metastatic Prostate Cancer. European Urology Open Science. 2026. PMID: 41561488